The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial

BACKGROUND: This study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine. METHOD: In a phase I randomized, double-blinded, placebo-controlled trial involving 192 healthy adults 18–59 years old, two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Jing, Yu, Qin, Yin, Zhifang, Zhang, Ying, Li, Xueqi, Yin, Qiongzhou, Chen, Hongbo, Long, Runxiang, Zhao, Zhimei, Mou, Tangwei, Zhao, Heng, Feng, Shiyin, Xie, Zhongping, Wang, Lichun, He, Zhanlong, Liao, Yun, Fan, Shengtao, Jiang, Ruiju, Wang, Jianfeng, Zhang, Lingli, Li, Jing, Zheng, Huiwen, Cui, Pingfang, Jiang, Guorun, Guo, Lei, Xu, Mingjue, Yang, Huijuan, Lu, Shan, Wang, Xuanyi, Gao, Yang, Xu, Xingli, Cai, Linrui, Zhou, Jian, Yu, Li, Chen, Zhuo, Hong, Chao, Du, Dan, Zhao, Hongling, Li, Yan, Ma, Kaili, Ma, Yunfei, Liu, Donglan, Yao, Shibao, Li, Changgui, Che, Yanchun, Liu, Longding, Li, Qihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040531/
https://www.ncbi.nlm.nih.gov/pubmed/33875266
http://dx.doi.org/10.1016/j.vaccine.2021.04.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040531/
https://www.ncbi.nlm.nih.gov/pubmed/33875266
http://dx.doi.org/10.1016/j.vaccine.2021.04.006

Ejemplares similares